Microbiome profile associated with malignant pleural effusion.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 04 02 2020
accepted: 08 04 2020
entrez: 9 5 2020
pubmed: 10 5 2020
medline: 30 7 2020
Statut: epublish

Résumé

There is ongoing research into the development of novel molecular markers that may complement fluid cytology malignant pleural effusion (MPE) diagnosis. In this exploratory pilot study, we hypothesized that there are distinct differences in the pleural fluid microbiome profile of malignant and non-malignant pleural diseases. From a prospectively enrolled pleural fluid biorepository, samples of MPE were included. Non-MPE effusion were included as comparators. 16S rRNA gene V4 region amplicon sequencing was performed. Exact Sequence Variants (ESVs) were used for diversity analyses. The Shannon and Richness indices of alpha diversity and UniFrac beta diversity measures were tested for significance using permutational multivariate analysis of variance. Analyses of Composition of Microbiome was used to identify differentially abundant bacterial ESVs between the groups controlled for multiple hypothesis testing. 38 patients with MPE and 9 with non-MPE were included. A subgroup of patients with metastatic adenocarcinoma histology were identified among MPE group (adenocarcinoma of lung origin (LA-MPE) = 11, breast origin (BA-MPE) = 11). MPE presented with significantly greater alpha diversity compared to non-MPE group. Within the MPE group, BA-MPE was more diverse compared to LA-MPE group. In multivariable analysis, ESVs belonging to family S24-7 and genera Allobaculum, Stenotrophomonas, and Epulopiscium were significantly enriched in the malignant group compared to the non-malignant group. Our results are the first to demonstrate a microbiome signature according to MPE and non-MPE. The role of microbiome in pleural effusion pathogenesis needs further exploration.

Identifiants

pubmed: 32384089
doi: 10.1371/journal.pone.0232181
pii: PONE-D-20-03163
pmc: PMC7209204
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0232181

Subventions

Organisme : Marie Curie
ID : MCCC-RP-14-A17178
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR002649
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

mSystems. 2017 Mar 7;2(2):
pubmed: 28289731
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Orphanet J Rare Dis. 2013 Jul 12;8:105
pubmed: 23844722
Expert Opin Med Diagn. 2013 May;7(3):275-87
pubmed: 23550710
Am J Clin Oncol. 2010 Aug;33(4):420-3
pubmed: 19858695
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Cancer Causes Control. 2008 Nov;19(9):895-907
pubmed: 18478344
Front Oncol. 2018 Oct 15;8:371
pubmed: 30374420
ISME J. 2011 Feb;5(2):169-72
pubmed: 20827291
Nat Rev Cancer. 2013 Nov;13(11):800-12
pubmed: 24132111
Front Microbiol. 2017 Dec 22;8:2591
pubmed: 29312264
J Clin Microbiol. 2012 Nov;50(11):3562-8
pubmed: 22915614
Nat Med. 2018 Apr 10;24(4):392-400
pubmed: 29634682
J Cell Physiol. 2019 Mar;234(3):2337-2344
pubmed: 30191984
Cancer Res. 2008 Dec 15;68(24):10060-7
pubmed: 19074871
Nature. 2017 Nov 23;551(7681):457-463
pubmed: 29088705
Am J Respir Crit Care Med. 2013 May 15;187(10):1118-26
pubmed: 23348972
PLoS One. 2011 Mar 31;6(3):e17479
pubmed: 21483846
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
World J Gastrointest Oncol. 2018 Mar 15;10(3):71-81
pubmed: 29564037
Curr Protoc Bioinformatics. 2011 Dec;Chapter 10:Unit 10.7.
pubmed: 22161565
Nature. 2012 Nov 8;491(7423):254-8
pubmed: 23034650
Cancer Lett. 2018 Feb 28;415:40-48
pubmed: 29197615
Science. 2017 Dec 15;358(6369):1443-1448
pubmed: 29170280
Future Oncol. 2011 Jun;7(6):737-52
pubmed: 21675837
Microbiome. 2015 Dec 01;3:66
pubmed: 26620848
FEMS Microbiol Ecol. 2010 Sep;73(3):577-86
pubmed: 20629751
Oncol Lett. 2018 May;15(5):6352-6360
pubmed: 29725395
Nat Methods. 2011 Jul 17;8(9):761-3
pubmed: 21765408
Clin Infect Dis. 2007 Dec 15;45(12):1602-9
pubmed: 18190323
Eur Respir J. 2018 Nov 8;52(5):
pubmed: 30262573
Stat Med. 2008 Jul 10;27(15):2865-73
pubmed: 17960576

Auteurs

Samira Shojaee (S)

Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University Medical Center, Richmond, VA, United States of America.

Anukriti Sharma (A)

Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA, United States of America.

Neil Gottel (N)

Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA, United States of America.
Scripps Institution of Oceanography, UCSD, San Diego, CA, United States of America.

Trinidad Sanchez (T)

Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University Medical Center, Richmond, VA, United States of America.

Jack A Gilbert (JA)

Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA, United States of America.
Scripps Institution of Oceanography, UCSD, San Diego, CA, United States of America.

Najib M Rahman (NM)

Oxford Respiratory Trials Unit, Oxford Centre for Respiratory Medicine, University of Oxford, Oxford, United Kingdom.
Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH